MicroStrategy
MSTR
NVIDIA
NVDA
Adobe
ADBE
Salesforce
CRM
Apple
AAPL
US Stock MarketDetailed Quotes
IKT Inhibikase Therapeutics
- 3.2000
- +0.0400+1.27%
Close Dec 20 16:00 ET
- 3.2700
- +0.0700+2.19%
Post 20:01 ET
215.02MMarket Cap-1.03P/E (TTM)
3.5000High3.0700Low1.80MVolume3.1300Open3.1600Pre Close5.78MTurnover17.59%Turnover RatioLossP/E (Static)67.19MShares4.200052wk High-400.00P/B32.76MFloat Cap1.120052wk Low--Dividend TTM10.24MShs Float70.8000Historical High--Div YieldTTM13.61%Amplitude0.7900Historical Low3.2070Avg Price1Lot Size
About Inhibikase Therapeutics Company
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in developing protein kinase inhibitor therapeutics to modify the course of Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. It also focuses on neurodegeneration and its lead program IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Ableson Tyrosine Kinases. The company was founded by Milton H. Werner in September 2008 and is headquartered in Atlanta, GA.
Company Profile
SymbolIKT
Company NameInhibikase Therapeutics
Listing DateDec 23, 2020
Issue Price10.00
Founded2008
CEODr. Milton H. Werner, PhD
MarketNASDAQ
Employees14
Fiscal Year Ends12-31
Address3350 Riverwood Parkway South East,Suite 1900
CityAtlanta
ProvinceGeorgia
CountryUnited States of America
Zip Code30339
Phone1-678-392-3419
Websitehttp://www.inhibikase.com
Company Executives
- Name
- Position
- Salary
- Dr. Milton H. Werner, PhD
- Director, President and Chief Executive Officer
- 811.43K
- Garth Lees-Rolfe
- Vice President, Finance and Chief Financial Officer
- --
- David Canner
- Director
- --
- Arvind Kush
- Director
- --
- Amit D. Munshi
- Director
- --
- Dennis N. Berman
- Independent Director
- 74.85K
- Dr. Roy Freeman, M.D.
- Independent Director
- 65.85K
- Dr. Terence A. Kelly, PhD
- Medicinal Chemistry and Drug Discovery Consultant
- --
- Roberto Bellini
- Chiarman of the Board
- --
- Warren Olanow
- Lead Medical Professional
- --
- Dr. Surendra Singh, PhD
- Head of Chemistry, Manufacturing and Controls
- --
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.